HIG Hartford (The)
Excellent insurer at peak-cycle ROE; 2x book already pays for a strong tomorrow.
The story
The Hartford is a high-quality specialty P&C and group benefits franchise printing peak-cycle 23% trailing ROE on four years of hard-market margin expansion (11.3% to 17.7% operating margins) and elevated investment yields. At ~2x book value, the market is capitalizing near-record underwriting profits that historically mean-revert as commercial pricing softens. Balance sheet and reserves are strong, but the cycle, not the franchise, is doing the heavy lifting on returns.
Trailing 23% ROE is clearly peak-cycle for P&C; I hold the through-cycle normalized ROE at 13.5%, which is already generous for this franchise and sits well above the 9% cost of equity. Book growth of 7% near term reflects strong retention, fading to 3.85% terminal (below the 5% risk-free rate) as buybacks and soft-market economics cap balance-sheet expansion. Facts since my last take have not changed — ROE is still elevated, price still ~2x book — so drivers stay put.
Value drivers
| Return on equity (normalized) | 13.5% |
| Book-value growth (Y1) | 7.0% |
| Terminal book growth | 3.9% |
| Beta | 0.88 |
| Failure probability | 0.5% |
| Cost of equity | 9.0% |
Valuation bridge
| PV of excess returns | 5.09B |
| PV of terminal excess | 5.25B |
| Equity value | 28.84B |
| ÷ shares → per share | $106.48 |
News
neutral +0.10 · 8 articles
- Is The Hartford Stock Underperforming the Dow?
- Chubb Limited's Life Business Emerges as a Key Growth Engine
- Hartford Insurance Group (HIG) Backs Energy Startups Through New Research Lab Partnership
- Is Hartford Insurance Group (HIG) Still Cheap After A 123% Run?
- 3 Inflated Stocks We Think Twice About
- Here's Why Investors Should Retain the Hartford Stock for Now
- Multi-Line Insurance Stocks Q2 Earnings Review: Hartford (NYSE:HIG) Shines
- Why Moderna Stock’s Historic Surge Is a Big Lesson for Markets
Projected excess returns on equity
| Yr | Book equity | ROE | Excess return | PV |
|---|---|---|---|---|
| 1 | 18.64B | 13.5% | 847.23M | 777.59M |
| 2 | 19.95B | 13.2% | 850.14M | 716.13M |
| 3 | 21.28B | 12.9% | 846.53M | 654.47M |
| 4 | 22.62B | 12.7% | 835.93M | 593.15M |
| 5 | 23.96B | 12.4% | 817.94M | 532.68M |
| 6 | 25.30B | 12.1% | 792.21M | 473.52M |
| 7 | 26.63B | 11.8% | 758.52M | 416.11M |
| 8 | 27.94B | 11.5% | 716.72M | 360.86M |
| 9 | 29.21B | 11.2% | 666.76M | 308.11M |
| 10 | 30.44B | 11.0% | 608.73M | 258.17M |
Key risks
- Commercial P&C pricing cycle softens, compressing underwriting margins from peak levels
- Elevated catastrophe losses or adverse reserve development in long-tail casualty lines
- Mark-to-market losses on the bond portfolio if rates back up sharply
Catalysts
- Sustained hard-market pricing and disciplined buybacks compounding book value faster than assumed
- Group benefits margin expansion and higher-for-longer investment yields lifting normalized ROE above 13.5%